Inhaled corticosteroids and COVID-19 outcomes in asthma - the Israeli experience
ERJ open research
; 2022.
Article
in English
| EuropePMC | ID: covidwho-1688524
ABSTRACT
Inhaled corticosteroids (ICS) alone or in combination with bronchodilators are widely used in asthma [1]. ICS have potential immunosuppressive effects which may promote viral replication, delayed viral clearance and increased risks of secondary infections [2, 3]. Furthermore, ICS use in asthma is associated with an increased risk of upper respiratory tract infections [2, 3]. Therefore, in the face of the current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection, concerns have been raised whether the use of ICS in asthmatic patients increase the risk of SARS CoV-2 infection and affect COVID-19 severity and mortality.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Language:
English
Journal:
ERJ open research
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS